ASCENDIS PHARMA BONE DISEASES A/S: Financial statements 2013
CVR: 32323596
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
ASCENDIS PHARMA BONE DISEASES A/S (CVR 32323596) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK -4,105,157 and a net result of DKK -4,115,409. Equity in the 2013 report amounted to DKK -3,993,238.
- Gross Profit
- DKK -4,105,157
- Profit/Loss
- DKK -4,115,409
- Equity
- DKK -3,993,238
- Total Assets
- DKK 2,313,647
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
On November 4, 2013, the company changed its name from ASCENDIS PHARMA RHEUMATOLOGY DIVISION A/S to ASCENDIS PHARMA OSTEOARTHRITIS DIVISION A/S.
On August 15, 2013, the company changed its name from ACP 30.06.2012 3 A/S to ASCENDIS PHARMA RHEUMATOLOGY DIVISION A/S.
ASCENDIS PHARMA BONE DISEASES A/S has published its interim report for the period June 29, 2012 – December 31, 2012.
About ASCENDIS PHARMA BONE DISEASES A/S
ASCENDIS PHARMA BONE DISEASES A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA OSTEOARTHRITIS DIVISION A/S and ASCENDIS PHARMA RHEUMATOLOGY DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 229,581,000 and a net result of EUR 134,982,000 compared with EUR -139,088 the year before. Equity in the 2025 report amounted to EUR -372,183,000.